Botox rivals are looming. That's why its new ads urge women—and men—to insist on the brand

botox
Revance and Mylan are readying a biosimilar competitor to Allergan blockbuster Botox. (Allergan)

Botox rivals are on the way, and to get out in front of them, Allergan is fielding a new ad push. Its aim: To get would-be users to ask for the blockbuster drug by name. Otherwise, they might get one of its newer competitors instead—and Allergan wouldn't like that one bit.

Two new spots for Botox Cosmetic—one aimed at men, the other at women—encourage viewers to name-drop the drug at the doctor’s office. In one, a male narrator reminds watchers that, “it’s the details that make the difference,” but “the man makes them matter” as the camera flips through shots of an architect showing his precise work to a child, a runner tying his shoes and setting his watch and a man fixing his collar and tie as he dresses in formalwear.

In the other, a female narrator encourages women to “face the world as a face to be reckoned with” over shots of a dancer practicing in the studio, a photographer shooting photos in the woods and a woman working with colleagues in the office. “Leave your mark on the world. Minimize its mark on you,” the voiceover says as the commercial ends.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Revance Therapeutics spooked Allergan investors in December when its Botox rival, candidate RT002, aced a pair of phase 3 trials. And the smaller company spooked the company again in February when it revealed a tie-up with Mylan to develop a biosimilar of the blockbuster product.

RELATED: Look out, Allergan: Doctor surveys show the 'Botox competitive threat is real'

Not all analysts are so worried about Allergan losing marketing share to Newark, California-based Revance. For one, Allergan has a whole suite of aesthetic remedies, and it cuts deals with doctors who use a lineup of them. “[T]he cash-pay bundle of aesthetics products that Allergan offers is a significant barrier to entry” for wannabe rivals, Leerink Partners’ Seamus Fernandez wrote in December.

And then there's the copycat version itself. RBC Capital Markets’ Randall Stanicky has noted that there are “several outstanding questions” around the Mylan biosimilar and how many of Botox’s many indications, both clinical and cosmetic, it’ll go after.

Plus, Wells Fargo’s David Maris pointed out in January that men and women seeking wrinkle relief already specify the Allergan injection. “[M]any patients demand Botox by brand”—and Allergan aims to keep that trend going with the new ads.

RELATED: Allergan moneymaker Botox grabs another cosmetic approval, this time in forehead lines

Investors aren’t necessarily buying into that optimism, and physician surveys predicted Revance will capture a good-sized piece of the pie. The “Botox competitive threat is real,” Bernstein’s Ronny Gal wrote in January.

Meanwhile, Allergan is still forging ahead with new uses for Botox, which executives have called a "pipeline in a drug." In October, it won a FDA green light to temporarily improve the appearance of forehead lines, an indication the company plugs in the new spots.

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.